ClinicalTrials.Veeva

Find clinical trials for Chronic Lymphocytic Leukemia in Valencia, VC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoid Leukemia
Lymphoma
B-Cell Lymphoma
Mantle-Cell Lymphoma
Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia trials near Valencia, VC, ESP:

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma....

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: CC-99282
Drug: Obinutuzumab

Phase 1

Celgene
Celgene

Valencia, Spain and 14 other locations

study includes patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lympho...

Enrolling
Small Lymphocytic Lymphoma
Relapsed/Refractory Chronic Lymphocytic Leukemia
Drug: Venetoclax
Biological: Epcoritamab

Phase 1, Phase 2

Genmab
Genmab

Madrid, Spain and 74 other locations

of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic...

Enrolling
Lymphoma, Small Lymphocytic
Leukemia, Chronic Lymphocytic
Drug: Nemtabrutinib
Biological: Rituximab

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Valencia, Valenciana, Comunitat, Spain and 42 other locations

The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely co...

Active, not recruiting
Chronic Lymphocytic Leukemia
Non Hodgkin Lymphoma
Drug: tafasitamab
Drug: parsaclisib

Phase 1, Phase 2

Incyte
Incyte

Valencia, Spain and 49 other locations

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

Phase 3

Loxo Oncology
Loxo Oncology

Valencia, Spain and 196 other locations

The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination wit...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Obinutuzumab

Phase 3

Acerta Pharma
Acerta Pharma

Valencia, Spain and 170 other locations

To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Rituximab
Drug: Venetoclax

Phase 3

BeiGene
BeiGene

Valencia, Spain and 178 other locations

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with...

Enrolling
Acute Mixed-Phenotype Leukemia
Small Lymphocytic Lymphoma
Drug: BMF-219

Phase 1

Biomea Fusion

Valencia, Spain and 40 other locations

venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medic...

Active, not recruiting
Lymphocytic Leukemia, Chronic
Drug: Venetoclax
Drug: Obinutuzumab

Phase 3

Roche
Roche

Valencia, Spain and 136 other locations

the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Idelalisib
Drug: Acalabrutinib (ACP-196)

Phase 3

Acerta Pharma
Acerta Pharma

Valencia, Spain and 156 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems